EdgarLookup

Coeptis Therapeutics Holdings, Inc. — Insider Transactions

Form 4 filings by directors, officers, and 10%+ shareholders

SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.

Overview All Filings Financials Insiders
Insider Title Type Shares Price Value Date
DeSilva Tara Purchase 1,800 $0.58 $1,044 Jan 12, 2024
Cogley Brian Chief Financial Officer Purchase 5,000 $0.67 $3,350 Jan 10, 2024
Mehalick David CEO and President Purchase 5,050 $0.69 $3,484 Jan 8, 2024
Yerace Daniel Alexander VP of Operations Purchase 10,850 $0.69 $7,486 Jan 5, 2024
Salkind Gene Purchase 11,600 $0.69 $8,004 Jan 5, 2024
Cochran Christopher P. Purchase 7,000 $0.77 $5,390 Jan 5, 2024
Mehalick David CEO and President Gift 700,000 Dec 7, 2023
Salkind Gene Purchase 28,638 $0.91 $26,061 Aug 29, 2023
Calise Chris Purchase 2,582 $0.94 $2,427 Aug 23, 2023
Harraden Circle Investors GP, LP Sale 85,305 $10.11 $862,434 May 4, 2022
GLAZER CAPITAL, LLC Sale 50,000 $9.85 $492,500 May 26, 2021
Calise Chris Chief Financial Officer Other 281,250 Dec 14, 2020
Striar Robert Chief Executive Officer Other 281,250 Dec 14, 2020
Bull Horn Holdings Sponsor LLC Other 281,250 Dec 14, 2020